Results 271 to 280 of about 113,350 (308)

Review on: Experimental Screening Methods for Antihypertensive Agents.

Mrunal K. Shirsat, Mrs. Shweta Bahire, Ms. Ashwini Dilip Patil, Ms. Vaibhavi.S. Bhosale   +3 more
openalex   +1 more source

Association of Weight Loss Composition Following Metabolic‐Bariatric Surgery With Incident Major Adverse Cardiovascular Events and All‐Cause Mortality

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT Severe obesity is associated with an increased cardiovascular risk. Metabolic‐bariatric surgery (MBS) can reduce the risk of cardiovascular events and mortality, potentially depending on weight loss composition. This study assessed the association between post‐MBS weight loss composition and major adverse cardiovascular events (MACE) and all ...
Malou A. H. Nuijten, Bente M. de Roos, Jan H. M. Karregat, Eric J. Hazebroek, Valerie M. Monpellier, Ignace M. C. Janssen, Maria T. E. Hopman, Esmée A. Bakker, Thijs M. H. Eijsvogels   +8 more
wiley   +1 more source

Uso de antihipertensivos en Cantabria (1995-2002): el desfase con las evidencias Use of antihypertensive agents in Cantabria, Spain [1995-2002]: discrepancy with the published evidence

, 2004
Luis Vara, Ana Sangrador, Pedro Muñoz, Saturnino Sanz   +3 more
openalex   +1 more source

Relation Between Adiposity Measures and the Risk of a Composite of Cardiovascular Events, Diabetes, and Cancer in Patients With Cardiovascular Disease

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT Adiposity contributes to multiple non‐communicable diseases. To guide prevention of morbidity, this study aimed to quantify the relation between waist circumference (WC), body mass index (BMI), waist to height ratio (WtHR), abdominal subcutaneous (SAT) and visceral adipose tissue (VAT) and the risk of a composite outcome including recurrent ...
Ritobrata Bhattacharya, Frank L. J. Visseren, Manon G. van der Meer, Martin Teraa, Jannick A. N. Dorresteijn, Ynte M. Ruigrok, Thomas T. van Sloten, on behalf of the UCC‐Smart Study Group, S. I. M. Bongers, J. L. P. van Giele, A. Vandersteen, M. J. Cramer, M. G. van der Meer, P. van der Harst, H. M. Nathoe, M. Teraa, M. van Smeden, M. H. Emmelot‐Vonk, P. A. de Jong, A. T. Lely, M. M. Mokhles, Y. M. Ruigrok, M. C. Verhaar, J. A. N. Dorresteijn, F. L. J. Visseren   +24 more
wiley   +1 more source

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim, Ingrid F. Metzger, Jessica Bo Li Lu, Todd C. Skaar, Zeruesenay Desta   +4 more
wiley   +1 more source

FDA Approved pediatric antihypertensive agents [PDF]

, 2014
Doshi, Ashish
core   +1 more source

Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 895-905, February 2026.
Abstract Aim A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide. Methods Glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
Abigail Postema, Jordy Gaspersz, Brenda N. Baak, Eline L. Huisman, Charlotte Hoogstraten, Lise Meinicke Hagelund, Fernie J. A. Penning‐van Beest, Jetty A. Overbeek   +7 more
wiley   +1 more source

Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study)

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 906-913, February 2026.
Abstract Aims To evaluate the lipid‐lowering efficacy, safety, and adherence of switching from moderate‐ or low‐intensity statin monotherapy to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus (T2DM) and dyslipidaemia.
Sangmo Hong, Won J. Kim, Sungrae Kim, Jung H. Park, Eun S. Kang, Min K. Moon, Jae T. Kim, Ji‐Oh Mok, Ki Y. Lee, Cheol‐Young Park, Chang B. Lee   +10 more
wiley   +1 more source

Early Initiation of Sacubitril/Valsartan in Intracerebral Hemorrhage With Refractory Hypertension and Chronic Heart Failure: A Case Report. [PDF]

Cureus
Nishino T, Yamaoka A, Komatsu K, Akiyama Y, Mikuni N.   +4 more
europepmc   +1 more source

Electro-encephalographic surrogate measures fail to describe the pharmacodynamic interaction between ketamine and propofol. [PDF]

, 2004
Mortier, Eric, Struys, Michel, VEREECKE, HUGO   +2 more
core   +1 more source